DK1263464T3 - Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion - Google Patents

Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion

Info

Publication number
DK1263464T3
DK1263464T3 DK01956188.5T DK01956188T DK1263464T3 DK 1263464 T3 DK1263464 T3 DK 1263464T3 DK 01956188 T DK01956188 T DK 01956188T DK 1263464 T3 DK1263464 T3 DK 1263464T3
Authority
DK
Denmark
Prior art keywords
tgf
prevention
treatment
renal impairment
antagonist anti
Prior art date
Application number
DK01956188.5T
Other languages
English (en)
Inventor
Steven R Ledbetter
Richard J Roman
Original Assignee
Genzyme Corp
Mcw Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22691635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1263464(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Mcw Res Foundation filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK1263464T3 publication Critical patent/DK1263464T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK01956188.5T 2000-03-09 2001-03-08 Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion DK1263464T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18806000P 2000-03-09 2000-03-09
PCT/US2001/007473 WO2001066140A1 (en) 2000-03-09 2001-03-08 Use of tgf-beta antagonists to treat or to prevent loss of renal function

Publications (1)

Publication Number Publication Date
DK1263464T3 true DK1263464T3 (da) 2013-01-28

Family

ID=22691635

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01956188.5T DK1263464T3 (da) 2000-03-09 2001-03-08 Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion

Country Status (10)

Country Link
EP (1) EP1263464B1 (da)
JP (1) JP2004502644A (da)
AU (1) AU2001272100A1 (da)
CA (1) CA2400628A1 (da)
DK (1) DK1263464T3 (da)
ES (1) ES2398039T3 (da)
HK (1) HK1047542A1 (da)
IL (2) IL151369A0 (da)
PT (1) PT1263464E (da)
WO (1) WO2001066140A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
EP1620128A1 (en) * 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP1843780A4 (en) * 2004-12-31 2010-03-17 Univ Queensland Methods of Treatment
AU2006244148A1 (en) * 2005-05-05 2006-11-16 Fibrogen, Inc. Cardiovascular disease therapies
DE602006021600D1 (de) * 2005-09-29 2011-06-09 Fibrogen Inc Verfahren zur senkung des blutdrucks
ITMI20060181A1 (it) * 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
WO2007121233A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
WO2007137584A1 (en) * 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
EP2029625A2 (en) * 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
DK2262520T3 (da) 2008-02-26 2017-08-07 Univ Cornell Sammensætninger til forebyggelse og behandling af nyreskader
WO2013068776A1 (en) * 2011-11-09 2013-05-16 Università Degli Studi Di Bari Combination of active ingredients for the treatment of acute kidney injury
ES2417679B1 (es) * 2011-12-09 2014-09-15 Servicio Andaluz De Salud Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria.
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
PT2971048T (pt) 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2015183995A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3149035A4 (en) 2014-05-28 2018-05-16 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
AU2021234121A1 (en) * 2020-03-11 2022-09-29 Universitaet Bern Fetuin A for treatment of renal disorders
US20250034212A1 (en) 2021-09-30 2025-01-30 Peptidream Inc. Peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO1991004748A1 (en) 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
ZA914750B (en) * 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
JPH08333249A (ja) * 1995-06-07 1996-12-17 Ono Pharmaceut Co Ltd ＴＧＦ−β放出、活性化および合成抑制剤
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease

Also Published As

Publication number Publication date
CA2400628A1 (en) 2001-09-13
ES2398039T3 (es) 2013-03-13
IL151369A (en) 2013-08-29
JP2004502644A (ja) 2004-01-29
AU2001272100A1 (en) 2001-09-17
PT1263464E (pt) 2012-12-17
HK1047542A1 (zh) 2003-02-28
IL151369A0 (en) 2003-04-10
WO2001066140A1 (en) 2001-09-13
EP1263464A1 (en) 2002-12-11
EP1263464B1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
DK1263464T3 (da) Anvendelse af antagonist anti-TGF-BETA-antistoffer til behandling eller til forebyggelse af tab af nyrefunktion
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DE60204827D1 (de) Anhebungsdetektion zur automatischen Sprachzusammenfassung
DE60126838D1 (de) Amidoacetonitrile zur Bekämpfung von Endoparasiten
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK199800837A (da) Anlæg til behandling af emner
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1572613T3 (da) Fremgangsmåde til fremstilling af benzophenoner
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK3103443T3 (da) Fremgangsmåde til behandling af primær søvnforstyrrelse
EP1445096A4 (en) IMPACT-RESISTANT FILM
NO20005023D0 (no) FremgangsmÕter for Õ hemme MRP1
DK1268482T3 (da) Pyranoindoler til behandling af glaukom